Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Abatacept can reduce racial disparities by mitigating the impact of mismatching in unrelated donor HCT
Qayed M, et al. – Research published in Blood Advances shows reductions in acute graft-versus-host disease (GVHD) in both matched unrelated and mismatched unrelated donor hematopoietic stem cell transplantation (MUD and MMUD HCT) when abatacept is added to standard of care treatment. Effects were substantial in MMUD, revealing abatacept as another promising tool to expand HCT access to those without a fully matched donor, which is more common for racially and ethnically diverse patients.
Study shows mismatched unrelated donor (MMUD) HCT using PTCY and bone marrow is safe and effective
Use of MMUDs can expand HCT access for ethnically diverse populations.
Auletta J, et al., Transplantation and Cellular Therapy—A manuscript published in Transplantation and Cellular Therapy offered the first report on the impact of the COVID-19 pandemic on the ability of the National Marrow Donor Program® (NMDP)/Be The Match® and the Network to safely deliver unrelated donor products early in the pandemic. The authors found that the NMDP/Be The Match and Network partners continued to effectively deliver domestic and unrelated donor products to allogeneic transplant patients in similar or shorter timeframes than before COVID-19, despite the many unexpected challenges brought about by the pandemic.
Subscribe to E-News
Receive new research summaries monthly.